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K5 lyase A (KflA) is a tailspike protein from the K5A
phage that catalyzes the degradation of the capsule poly-
saccharide of K5 strains of Escherichia coli. The K5
E. coli capsule polysaccharide, also known as heparosan,
is composed of the disaccharide repeating unit of [-4)-
GlcA-β(1,4)-GlcNAc-α(1-] and therefore identical to the
biological precursor of heparin and heparan sulfate (HS).
KflA could supplement the heparin lyases for heparin and
HS analysis. The first part of this study aimed to clarify
ambiguity resulting from the revision of the KflA amino
acid sequence in 2010 from that published in 2000. We
found that only the expression of the updated sequence
gave a soluble active enzyme, which produced heparosan
degradation products similar to those of previous studies.
Next, we examined the specificity of KflA toward heparo-
san oligosaccharides of varying sizes, all containing a
single N-sulfated glucosamine (GlcNS) residue. The pres-
ence of GlcNS in an octasaccharide and a nonasaccharide
chain directed cleavage by KflA to a single position at the
reducing end of the substrate. However, an N-sulfated dec-
asaccharide exhibited extensive cleavage at the nonredu-
cing end of the chain, illustrating a distinct change in the
cleavage pattern of KflA toward substrates of differing
sizes. Because KflA is able to cleave a substrate containing
isolated GlcNS residues, this enzyme could be used for the
analysis of low-sulfate content HS domains.
Keywords: heparan sulfate / heparin / heparosan / lyase /
oligosaccharide
Introduction
K5 lyase A (KflA) is a viral tailspike protein from the K5A
bacteriophage that infects the K5 strain of Escherichia coli
(Hänfling et al. 1996). The K5 strain of E. coli possesses a
polysaccharide capsule that is composed of heparosan, a
glycosaminoglycan with the repeating disaccharide unit:
[-4)-GlcA-β(1,4)-GlcNAc-α(1-] (Roberts 1996). This polysac-
charide capsule is recognized by the K5A phage and allows for
host specificity, but the capsule must be penetrated for the phage
to access the entry receptor on the cell surface. To accomplish
this, KflA molecules on the phage tailspike bind and depoly-
merize the heparosan capsule and expose the viral entry receptor
(Clarke et al. 2000; Leiman et al. 2007). KflA follows the
general mechanism of the large class of polysaccharide-
degrading enzymes called polysaccharide lyases (Garron and
Cygler 2010). It cleaves heparosan by catalyzing a β-elimination
reaction at C-4 of glucoronic acid (GlcA), which breaks the
glycosidic bond and yields a Δ4,5 unsaturated GlcA at the nonre-
ducing terminus of the oligosaccharide product (Clarke et al.
2000). Although it is believed to follow a catalytic mechanism
like that of other polysaccharide lyases, the structure of KflA
most closely resembles that of glycoside hydrolases in the
GH90 family, many of which are also phage tailspike proteins
serving an analogous function in viral entry (Garron and Cygler
2010). These tailspike proteins, including KflA, all feature
homotrimeric parallel β-helix architecture (Barbirz et al. 2008;
Thompson et al. 2010). It has been proposed that the intensive
structural similarity of the phage tailspike proteins indicates an
evolutionary relationship in spite of their lack of significant
sequence homology (Jenkins et al. 1998; Barbirz et al. 2008).
The enzyme KflA and K5 strain of E. coli have been of
interest in the field of heparin and heparan sulfate (HS) glyco-
biology, because the K5 capsule polysaccharide is structurally
identical to the biosynthetic precursor of heparin and HS.
Heparin and HS function in a wide variety of processes in
mammals and have roles that include blood coagulation, cell
proliferation and development (Lindhardt 2003). During syn-
thesis by the cell, heparosan is assembled by glycosyltrans-
ferases and enzymatically modified in several ways:
deacetylation and subsequent N-sulfation of GlcNAc, epimeri-
zation of GlcA to iduronic acid (IdoA), sulfation of the 2-OH
on GlcA or IdoA and sulfation of 6- and 3-OH groups on
N-acetylglucosamine (GlcNAc) or N-sulfated glucosamine
(GlcNS; Lindhardt 2003). This results in a highly variable,
heterogenous pattern of sulfation and epimerization in the
chain. The tendency of polysaccharide lyases to cleave these
complex substrates in a predictable manner has made them im-
portant tools in glycosaminoglycan research (Michaud et al.
2003; Sasisekharan et al. 2006). The bacterial polysaccharide
lyases include three heparin lyases (heparinases I, II and III)
that have been integral to many advances in the understanding
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of heparin and HS biology, such as the identification of the
antithrombin-binding site on heparin that is responsible for its
anticoagulant properties (Lindahl et al. 1979). More recently,
KflA has been used to propose a structure for HS consisting of
highly sulfated regions interspersed with unmodified domains
possessing the heparosan-like structure and domains with inter-
mediate levels of sulfation (Murphy et al. 2004). KflA has also
been used to identify vascular endothelial growth factor-
binding sites in HS (Robinson et al. 2006). Both of these
experiments exploit the specificity of KflA for heparosan that
has not been modified by sulfation or epimerization. The
potential for further applications of KflA in heparin and HS
research make it an attractive target for investigation.
There were two primary goals in this study. The first origi-
nated with the revision of the amino acid sequence of KflA
(GenBank accession number CAA71133.2) that accompanied
the publication of its crystal structure in 2010 (Thompson
et al. 2010). In 2000, the protein sequence CAA71133.1 was
published alongside a study that identified the gene for KflA
within the K5 phage genome and described the expression of
recombinant KflA (Clarke et al. 2000). Figure 1 shows a
partial alignment of the two sequences of the regions with the
most consecutive mismatches. There are a total of 42 mis-
matched amino acid residues between the two sequences. In
the period after the first sequence was published, but before it
was revised in 2010, a number of fundamental biochemical
studies were done with KflA. It was not completely clear that
the sequence was used for these studies, which included
experiments on the specificity of KflA. Therefore, before be-
ginning further experiments on the specificity of KflA, we
wanted to be certain that the same protein sequence had been
used throughout the earlier studies on KflA and that there was
simply a mistake in the sequence data.
Our second goal was to assess the substrate specificity of
KflA using synthetic oligosaccharide substrates. Products
from treating the substrates with KflA were characterized by
mass spectrometry. A similar strategy has been successfully
employed by other groups on heparinases I and II (Ernst et al.
1998; Rhomberg et al. 1998). Previous studies on the specifi-
city of KflA have focused on polymeric glycosaminoglycans
and have shown that KflA does not degrade chondroitin
sulfate, heparin, hyaluronic acid, N-sulfo heparosan or chem-
ically desulfated N-acetylated heparin (Murphy et al. 2004;
Rek et al. 2007). HS showed modest amounts of degradation
by KflA, which was correlated with cleavage at regions pos-
sessing the heparosan-like structure (Murphy et al. 2004).
Earlier work has also investigated the minimum size of sub-
strates required for cleavage by KflA, and it was reported that
heparosan decasaccharide was fully degraded, while octasac-
charide and hexasaccharide left 50 and 90% undigested, re-
spectively (Murphy et al. 2004). The heparosan-degrading
activity of KflA was first observed in whole K5 phage parti-
cles, where it was reported to cleave the substrate with a
random, endolytic mode of action (Hänfling et al. 1996).
However, the cleavage of heparosan with K5 phage particles
also gave larger-sized oligosaccharide products (decasacchar-
ides to hexasaccharides) than the mixture of octasaccharides
to disaccharides observed when heparosan is cleaved with the
recombinant KflA enzyme (Hänfling et al. 1996; Murphy
et al. 2004; Blundell et al. 2009). The reason for this differ-
ence is not clear.
Here, we have set to understand the specificity of KflA, espe-
cially with regard to isolated GlcNS residues and the substrate
size. Up to this time, KflA has not been studied using structural-
ly homogeneous sulfated oligosaccharides, so we expect this
approach should move toward a more consistent understanding
of its specificity and insight into its mode of action. We synthe-
sized a series of oligosaccharide substrates for KflA based on
the structure of heparosan and established the effect of a single
GlcNS in the oligosaccharide chain. In the N-sulfated
Fig. 1. (A) There are a total of 42 mismatched amino acids in the two published sequences for KflA (CAA71133.1 from 2000 and CAA71133.2 from 2010).
Shown here are 38 of the mismatches that are mostly concentrated in three rows of the alignment of the two sequences. (B) Expression of CAA71133.2 gave
soluble, active protein with the expected molecular mass (56.3 kDa theoretical for post-translationally cleaved protein).


























octasaccharide (Octa-4) substrate, no cleavage was seen at the
[GlcNS-GlcA] bond; however, in an N-trifluoroacetylated
octasaccharide (Octa-3), the [N-trifluoroacetyl glucosamine
(GlcNTFA)-GlcA] bond was cleaved. Additionally, Octa-4 was
only cleaved on the reducing side of the GlcNS. We elongated
the Octa-4 substrate at the nonreducing end one sugar residue at
a time, which allowed the GlcNS to be retained in the same rela-
tive position. When the substrate was extended to Deca-6, cleav-
age was observed on both the nonreducing and reducing sides
of the GlcNS residue. Our study advances the understanding of
the substrate specificity of KflA, providing an additional tool to
analyze the structures of HS.
Results
Sequence CAA71133.2 gives a soluble and active enzyme
A recent paper in 2010 reports substantial changes in the amino
acid sequence of KflA compared with the gene for KflA that was
first identified in 2000 (Thompson et al. 2010). In the 10-year
period between 2000 and 2010, a number of studies were done
characterizing the biochemistry of KflA. To verify the sequence,
we expressed and purified KflA protein based on the Genbank
sequences for both CAA71133.1 (the sequence published in
2000) and CAA71133.2 (the sequence published in 2010). Both
sequences were expressed in E. coli as (His)6-tagged fusion pro-
teins and purified on a nickel-Sepharose column. Only the se-
quence CAA71133.2 yielded a protein with measurable activity
and gave a band near the 56.3-kDa size as determined with
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) (Figure 1). While the estimated molecular weight
(70.9 kDa) is larger than the apparent value, a post-translational
protease cleavage is speculated. It is believed that the C-terminal
end of KflA from Ser505 is autocatalytically cleaved to remove a
14.6-kDa autochaperone fragment from the initial 70.9-kDa
protein (Thompson et al. 2010). To verify that the CAA771133.1
was being expressed, but in an insoluble form, we included a
control where the CAA771133.1-containing vector was present
but was not induced with isopropyl-β-D-thiogalactopyranoside.
The 65-kDa band was only seen in the sample where expression
was induced, but this band was not visible in the supernatant
from the centrifugation step that followed cell lysis
(Supplementary data, Figure S1). The lack of solubility for
CAA771133.1 could be indicative of the full amino acid se-
quence that has not undergone the post-translational autocatalytic
cleavage that removes a 14.6-kDa C-terminal fragment from the
protein, yielding an insoluble form of protein. The C-terminal
region from Ser505 contains 17 of the 42 total amino acid mis-
matches, possibly destabilizing the autochaperone and autocata-
lytic function that has been proposed to be associated with this
region of the sequence (Thompson et al. 2010).
N-sulfo heparosan and 6-O-sulfo heparosan
are not substrates for KflA
To verify that sequence CAA71133.2 encodes an active lyase,
we evaluated the oligosaccharide products formed when hepar-
osan was incubated with KflA. The elution profile of
KflA-degraded heparosan from a BioGel P-10 column is
shown in Figure 2A. The absorbance at 232 nm, which corre-
sponds to the Δ4,5 unsaturated glucuronic acid product of KflA
cleavage (as depicted in Figure 2D), was used to monitor the
presence of product in fractions. Electrospray ionization mass
spectrometry (ESI-MS) confirmed the identity of the peaks that
are labeled in Figure 2A. Both the elution profile and indenti-
fies of the products were largely consistent with those pub-
lished in earlier work by other groups, namely the products are
mixtures of oligosaccharides ranging from di- to octasacchar-
ides (Murphy et al. 2004; Blundell et al. 2009).
Next we set out to assess whether N-sulfo heparosan or
6-O-sulfo heparosan could act as a substrate for KflA. Both
substrates were 35S-radiolabeled as described in “Experimental
Procedures”. N-[35S]-sulfo heparosan and 6-O-[35S]sulfo
heparosan were incubated with KflA overnight. After incuba-
tion, the reaction mixture was separated on a BioGel P-10
column, and the plots of counts per minute (CPM) vs. fraction
were compared with the plot of a control consisting of the
respective sulfated heparosan incubated without the enzyme.
As illustrated in Figure 2B and C, N-sulfo heparosan and
6-O-sulfo heparosan treated with KflAwere eluted the same as
those of undigested polysaccharide substrates, suggesting that
neither served as a substrate for KflA. With respect to
N-sulfated heparosan, our result here confirmed that of others,
which showed N-sulfated heparosan is not cleaved (Murphy
et al. 2004). The effect of 6-O-sulfation on KflA substrate had
not been assessed previously.
Minimum size of the KflA substrate
To determine the minimum length of substrate required for
cleavage by KflA, we exposed the lyase to hexa- and octasac-
charides. Both oligosaccharide substrates were isolated from
KflA-degraded heparosan, and their structures were confirmed
by ESI-MS as shown in Table I. The digestion reaction was
carried out by incubating Δ4,5 hexasaccharide (Hexa-1) and
Δ4,5 octasaccharide (Octa-2) with KflA, and the products were
analyzed by the BioGel P-2 column coupled with ESI-MS
(Figure 3). Octa-2 was almost fully degraded to yield di-, tetra-
and hexasaccharides (Figure 3A and B). For example, the ana-
lysis of fraction 51 revealed a strong signal at the m/z value of
1136.6, along with 1158.5 m/z and 568.1 m/z. Taking these
values as the [M−H]−, [M−H+Na]− and [M−2H]2− fragments,
respectively, these indicate an oligosaccharide product with a
molecular weight of 1137.7 ± 0.4 (Figure 3B). This measure-
ment is very close to the calculated molecular weight of
1137.3 for a hexasaccharide with a structure of ΔUA-GlcNAc-
GlcA-GlcNAc-GlcA-GlcNAc. The exposure of Hexa-1 to
KflA resulted in mostly (undigested) hexasaccharide along
with only a small amount of disaccharide, suggesting that
Hexa-1 was resistant to digestion (data not shown). Our data
suggest that octasaccharide is the minimum size for KflA di-
gestion, which is consistent with the previous publication
(Murphy et al. 2004). Based on this conclusion, our subse-
quent studies were focused on using substrates at least as large
as octasaccharides to further investigate the substrate specifi-
city of KflA.
Effect of a single N-sulfation on cleavage of octasaccharide
substrate
We determined the contribution of N-sulfation to the suscepti-
bility to degradation by KflA using a series of synthetic


























oligosaccharides. To this end, a total of four oligosaccharides,
ranging from octa- to decasaccharides, were synthesized
(Octa-3 to Deca-6, Table I). The detailed procedures for
the synthesis of these oliogsaccharides are described in
“Experimental Procedures”. The results from ESI-MS analysis
confirmed the identity of the anticipated products (Table II–IV).
To first determine the sites cleaved by KflA for substrate
lacking N-sulfation, we began with the octasaccharide shown
Fig. 2. Heparosan depolymerization by KflA gives a mixture of octasaccharides through disaccharides. These were identified by P-10 fractionation of the
depolymerization products followed by scanning fractions at 232 nm and confirming peaks with ESI-MS. N-[35S]sulfo heparosan and 6-O-[35S]sulfo heparosan
were treated with KflA or with vehicle. P-10 fractions show experimental and control samples elute in the same range and indicate that the enzyme was
nonreactive with these polymers.
Table I. Summary of oligosaccharide substrates
Abbreviated structures Calculated MW Measured MW
Hexa-1 ΔUA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc 1137.3 1138.2 ± 0.5
Octa-2 ΔUA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-GlcNAc 1516.4 1517.1 ± 0.4
Octa-3 GlcNAc-GlcA-GlcNTFA-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP 1709.4 1710.2 ± 0.1
Octa-4 GlcNAc-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP 1693.4 1694.4 ± 0.1
Nona-5 GlcA-GlcNAc-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP 1869.5 1870.4 ± 0.1
Deca-6 GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP 2072.5 2073.4 ± 0.1


























in Figure 4A. In Octa-3, the third sugar residue from the non-
reducing end is a GlcNTFA residue. The GlcNTFA residue is
a bioisostere of GlcNAc, and it can be readily converted to a
GlcNS via chemoenzymatic methods (Masuko et al. 2012). In
addition, a para-nitrophenol (pNP) group is attached to the
reducing end of the substrate, which is used as a means for
ultra violet detection (monitored at 310 nm). The substrates
were incubated with KflA, and the products were analyzed by
BioGel P-2 and ESI-MS. The plots of A310 vs. fraction
number illustrate the relative amounts of the pNP-tagged
species and are shown in Supplementary data, Figure S2. The
summary of these analyses is shown in Tables II–IV. For
Octa-3 substrate, degradation with KflA yielded four products
(Figure 4A), indicative of two sets of cleavages by KflA
(Table II). One cleavage occurred at position 2, yielding
pentasaccharide(a) and trisaccharide(b); another cleavage
occurred at position 3, yielding trisaccharide(c) and pentasac-
charide(d). Our data also confirmed that neither the pNP
group nor the TFA substitution on the glucosamine residue
affects the susceptibility to degradation by KflA.
After establishing the pattern of cleavage for Octa-3, the
TFA group was exchanged with an N-sulfate to give Octa-4.
The digestion of Octa-4 with KflA only yielded two products
(Figure 4B), suggesting that only a single cleavage occurred
on this substrate. Analysis with BioGel P-2 and ESI-MS
revealed that the cleavage site is located at position 2. The
lack of products corresponding to cleavage at position 3
demonstrates that KflA is unable to cleave the linkage consist-
ing of –GlcNS-GlcA–.
The effect of the GlcNS residue on the KflA cleavage
pattern was further investigated by extending the length of the
oligosaccharide substrates. The addition of one GlcA to the
nonreducing end of Octa-4 resulted in Nona-5. The digestion
pattern of Nona-5 to KflA is very similar to that observed for
Octa-4 (Figure 4B and Table III), namely only single cleavage
was observed. The addition of another GlcNAc residue to
Nona-5 yielded Deca-6. Incubation of Deca-6 with KflA
resulted in a more complex mixture of products. The results
from product analysis revealed that KflA cleaved on three sites
in Deca-6 (Figure 4C): the first scenario is to cleave at position
5 to yield a nonasaccharide(g) and a monosaccharide product.
Indeed, we observed the presence of nonasaccharide(g) in the
product by ESI-MS analysis. The second scenario is to cleave
at position 4, yielding trisaccharide(h) and hexasaccharide(i).
Both trisaccharide(h) and hexasaccharide(i) were observed by
ESI-MS (Table IV). The third scenario is to cleave at position
2, resulting in trisaccharide(b) and hexasaccharide( j). In add-
ition, hexasaccharide( j) was further degraded to tetrasacchar-
ide(k). All these oligosaccharide products were observed by
ESI-MS (Table IV). As expected, no cleavage at position 3
was found.
Discussion
Polysaccharide lyases are valuable tools for glycosaminogly-
can research, and KflA itself has already been shown to be
useful in the study of the structure of HS. Understanding its
Fig. 3. (A) The possible products from KflA catalyzed degradation of the Δ4,5 octasaccharide, Octa-2. The theoretical molecular weights of each of the fragments
are also shown. (B) BioGel P-2 fraction absorbance profile from KflA cleavage of Octa-2. ESI-MS confirmed the identity of the peak fractions.


























specificity toward single sulfations of the heparosan substrate
could further extend the applications of KflA in heparin and
HS analysis. Here, we demonstrate that only Genbank
sequence CAA71133.2 produced a soluble and active KflA
enzyme. The degradation of polymeric heparosan with
CAA71133.2 gave a product profile similar to that seen using
KflA before the sequence was corrected in 2010 (Murphy et al.
2004). Through comparing our results with those published by
other groups, it seems likely that CAA71133.1 was never used
in the previous studies and was reported as the result of errors
in gene sequencing. However, there were anomalies in the
work that first identified and sequenced the KflA gene that led
us to question, which protein sequence was used for this study.
Their SDS–PAGE result shows a band at approximately 67
kDa, which is much closer to the 70.9 kDa expected for the
full peptide than 56.3 kDa for the post-translationally cleaved
product (Clarke et al. 2000). Our SDS–PAGE experiment gave
a band positioned near 56 kDa, which corresponds to the
removal of the 14.6-kDa segment. The crystal structure of
KflAverifies that this segment is excised in the mature protein
(Thompson et al. 2010). It is unclear why CAA71133.1 failed
to give a soluble product. There are 17 of the 42 total mis-
matched amino acids from the sequence alignment clustered at
the C-terminal end of CAA771133.1 (from Ser505 to the
C-terminus), which could disrupt the autochaperone and auto-
catalytic functions associated with this region (Thompson
et al. 2010).
In this article, we used defined oligosaccharides ranging
from oligosaccharides to decasaccharides to show that KflA is
sensitive to the presence of GlcNS residues. We have also
shown that the glycosidic bond consisting of [GlcNS-GlcA] is
resistant to degradation by KflA. Replacing the GlcNS residue
with the GlcNAc bioisostere, GlcNTFA renders this bond sus-
ceptible to cleavage. Although the oligosaccharides were not
fully digested, the extent of cleavage can be enhance by
adding more KflA enzyme or prolonging the incubation time
(Rek et al. 2007).
Our data show that heparosan substrates smaller than an
octasaccharide are no longer susceptible to degradation. At
the same time, incubation of KflA with polymeric heparosan
results in mostly disaccharide products (Figure 2). Using a
model of random endolytic cleavage by KflA (Hänfling et al.
1996), one would expect the majority of the products to be
larger than hexasaccharides. A model of processive cleavage
by polymeric heparosan KflA could explain the predominance
of tetrasaccharides and disaccharides that is observed. Indeed,
Table III. ESI-MS and BioGel P-2 analysis of KflA digested Octa-4 and Nona-5
Substrates Abbreviated structures Fraction# from BioGel P2 Calculated MW Measured MW
Octa-4 GlcNAc-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP – – –
Products
e GlcNAc-GlcA-GlcNS-GlcA-GlcNAc 35 1017.3 1017.4




f GlcA-GlcNAc-GlcA-GlcNS-GlcA-GlcNAc 35 1193.3 1194.1 ± 0.6
b ΔUA-GlcNAc-GlcA-pNP 47 676.2 676. 4 ± 0.1
Table IV. ESI-MS and BioGel P-2 analysis of KflA digested Deca-6
Substrates Abbreviated structures Fraction# from BioGel P2 Calculated MW Measured MW
Deca-6 GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP – – –
Products
b ΔUA-GlcNAc-GlcA-pNP 49 676.5 676.4 ± 0.1
g ΔUA-GlcNAc-GlcA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP 31 1852.5 1852.4 ± 0.6
h GlcNAc-GlcA-GlcNAc 41 600.5 600.5 ± 0.1
i ΔUA-GlcNS-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP 34 1473.2 1473.4 ± 0.2
j GlcNAc-GlcA-GlcNAc-GlcA-GlcNS-GlcA-GlcNAc 32 1397.2 1397.6 ± 0.1
k ΔUA-GlcNS-GlcA-GlcNAc 37 796.7 796.4
Table II. ESI-MS and BioGel P-2 analysis of KflA digested Octa-3
Substrates Abbreviated structures Fraction# from BioGel P2 Calculated MW Measured MW
Octa-3 GlcNAc-GlcA-GlcNTFA-GlcA-GlcNAc-GlcA-GlcNAc-GlcA-pNP – – –
Products
a GlcNAc-GlcA-GlcNTFA-GlcA-GlcNAc 35 1033.3 1033.5
b ΔUA-GlcNAc-GlcA-pNP 44 676.2 676.4 ± 0.1
c GlcNAc-GlcA-GlcNTFA 41 654.2 654.4
d ΔUA-GlcNAc-GlcA-GlcNAc-GlcA-pNP 36 1055.3 1055.4 ± 0.04


























a processive cleavage model for the K1-5 phage has been
proposed (Leiman et al. 2007).
It is apparent that the size of the substrate has effects on the
cleavage pattern of KflA. All three of the synthetic substrates
have a common cleavage site at position 2. However, when the
substrate is extended to Deca-6, there is a dramatic change in
the cleavage pattern by KflA (Figure 4). For instance, position
4 is not susceptible for cleavage in Nona-5, but is cleaved in
Deca-6. The basis for this is unclear based on our understand-
ing of the crystal structure of KflA. This work does show that
KflA is able to recognize and cleave domains containing iso-
lated GlcNS residues. Therefore, it may be possible to use
KflA for illuminating the detailed structure of HS domains
with low-sulfate content. However, the variable cleavage pat-
terns of KflA due to substrate size effects should be accounted
for when using KflA for HS structural analysis.
Materials and methods
Expression and purification of (His)6-tagged KflA
The cDNA for KflA with NCBI GenBank accession numbers
CAA71133.2 and CAA71133.1 were purchased from
GenScript optimized for expression in E. coli, in plasmid
pUC57. The same protocol was used for both CAA71133.2
and CAA71133.1. The primers 5′-AGTACATATGATGGCAA
AACTGACCAAACCG-3′ and 5′- AGGAGGATCCTTACTTC
GGCAGGGCGGCCAG-3′ were synthesized (Invitrogen, NY).
The restriction sites for Nde1 and BamH1, respectively, are
underlined. Amplification via polymerase chain reaction con-
sisted of 5 min at 95°C, then 25 cycles of the following: 30 s
at 94°C, 30 s at 52°C, 2.5 min at 68°C and a final period of 10
min at 68°C. The vector pET-15b and the cDNA were treated
with Nde1 and BamH1 and ligated using the manufacturer’s
protocol from the DNA rapid ligation kit (Roche, IN). E. coli
DH5α (Invitrogen) was transformed with the ligation product,
colonies from the transformation were shaken overnight in 3
mL Luria-Bertani (LB) media with carbenicillin (50 μg/mL for
all LB media), and plasmid was extracted following the manu-
facturer’s protocol with the QIAprep Spin Miniprep Kit
(Qiagen, Hilden, Germany). Samples of purified plasmid were
treated successively with Nde1 and BamH1 and resolved on
5% agarose gel to identify correctly ligated plasmids for se-
quencing (Genome Analysis Core Facility, University of North
Carolina, CA). Plasmids (KflA in pET-15b) were transformed
into BL21* E. coli (Invitrogen), and colonies were shaken in
3 mL LB media overnight (37°C), added to 100 mL LB media
Fig. 4. The cleavage of synthetic N-trifluoroacetylated or N-sulfated oligosaccharides by KflA. (A) The third sugar residue from the Octa-3 substrate at the
nonreducing end is a GlcNAc bioisostere, GlcNTFA. The products identified by ESI-MS correspond to cleavage at two positions at the reducing side of the
GlcNTFA. (B) Replacement of the trifluoroacetyl group with a sulfate eliminates cleavage at the [GlcNS-GlcA] bond, a result observed in all N-sulfated
substrates. The N-sulfated substrates Octa-4 and Nona-5 are both cleaved at position 2. (C) The N-sulfo decassacharide Deca-6 was lysed at positions 2, 4 and 5,
with two sites on the nonreducing side of GlcNS. The presence of fragment (k) indicates that some chains were cleaved multiple times.


























and grown to A600 between 0.6 and 0.8 at 37°C, then cooled to
22°C and induced with isopropyl-β-D-thiogalactopyranoside
(20 mM). The induced cells were shaken at 22°C for 18 h and
harvested by centrifugation (4000 × g, 12 min, 5°C). The pellet
was suspended in ice cold buffer A (25 mM Tris–HCl, 500
mM NaCl, 40 mM imidazole, pH 8.5) and lysed with 3 × 30 s
rounds of sonication (Branson, 45% duty cycle, power output
9), followed by centrifugation (15,000 × g, 30 min, 5°C).
Supernatant was filtered (Millipore, 45 μm) and loaded on a
nickel sepharose column (GE Healthcare, Uppsala, Sweden,
700 μL bed volume; Bio-Rad 0.8 × 4 cm, 0.5 mL/min). The
column was washed with 75 mL buffer A and eluted with 1
mL buffer B (25 mM Tris–HCl, 500 mM NaCl, 40 mM imid-
azole, pH 8.5). The quantity of protein was estimated by A280,
with 0.72 for sequence CAA71133.2 and 0.14 for
CAA71133.1. Each eluent was tested for activity by adding
1 μL eluent to 3 μg of heparosan in 100 μL (Tris–HCl 25 mM,
pH 8.5) and monitoring A232 and A280, with only CAA71133.2
showing significant (42%) increase in A232 over a 1-min
period. Analyzed with 12% SDS–PAGE, eluent from protein
CAA71133.2 ran at purity judged to be ≥90%, while no signifi-
cant band was visible for eluent from sequence CAA71133.1.
To test CAA71133.1 cells for the expression of insoluble
protein, approximately 10 μL of pellet from the postlysis centri-
fugation of CAA71133.1 was added to 20 μL water and 20 μL
Laemelli buffer (5% β-mercaptoethanol), then boiled for 10 min
to give a strong band at 65 kDa. Postlysis supernatant from
CAA71133.1 was also used for. Finally, a 100 μL sample of
cells for CAA71133.1 taken directly after induction and incuba-
tion, harvested by tabletop centrifuge (5300 × g, 3 min), dec-
anted, suspended in 20 μL water and 20 μL Laemlli buffer (5%
β-mercaptoethanol) and boiled for 10 min prior to 12% SDS–
PAGE.
Expression and purification of sulfotransferases
and glycosyltransferases
The synthesis of the N-sulfated and N-trifluoroacetylated oligo-
saccharides and sulfated heparosan required the enzymes
N-sulfotransferase (NST), 6-O-sulfotransferase isoforms 1 and
3 (6-OST-1, 6-OST-3), N-acetylglucosaminyltransferase (KfiA)
and Pasteurella multocida heparosan synthase (pmHS2). The
expression and purification of these enzymes has been
described before (Chen et al. 2005, 2007). Briefly, the enzymes
were expressed in E. coli as fusion proteins and purified ac-
cordingly, with NST tagged to a glutathione S-transferase and
purified on a glutathione sepharose column (GE Healthcare),
while 6-OST-1 and 6-OST-3 were expressed as maltose-
binding protein fusions and purified on an amylose column
(GE Healthcare). Both KfiA and pmHS2 were expressed as
(His)6 -tag fusions and purified on a nickel sepharose column
(GE Healthcare).
Heparosan incubation with KflA
A solution of 5 mg/mL heparosan (molecular weight 30
kDa; Volpi 2004) was incubated with 9.0 μg of KflA in a total
volume of 1 mL (25 mM HCl, pH 8.5) for 2 h at 37°C. The
method used for the production of heparosan is described in
section “Synthesis of heparosan”. The crude reaction mixture
was mixed with 1 μL 0.5% phenol red and separated on a
BioGel P-10 column (BioRad, 0.75 × 200 cm) with an elution
buffer containing 20 mM Tris–HCl and 1 mM NaCl (pH 7.5)
at a flow rate of 3 mL/h. The absorbance of each fraction was
measured at 232 nm. The absorbance vs. fraction number plot
shown in Figure 2 was constructed, and the three fractions
with the highest absorbance for each of the four prominent
peaks were pooled. Prior to analysis with mass spectrometry,
these were either desalted by dialysis or BioGel P-2. The
pooled fractions corresponding to the peak eluting last were
assumed to be disaccharide. We desalted a 0.5-mL sample of
these pooled fractions (with 1 μL 0.5% phenol red) with
BioGel P-2 (Biorad) in 0.1 M ammonium bicarbonate with a
flow rate of 3 mL/h. The other pooled fractions from the P-10
separation were dialyzed against 20 mM ammonium bicarbon-
ate using molecular weight cutoff (MWCO) 3500 membrane
and dried. Each sample was identified by ESI-MS analysis.
N-[35S]-sulfo heparosan and 6-O-[35S]-sulfo heparosan
incubation with KflA
N-[35S]-sulfo heparosan (10,000 CPM, 0.4 μg in 30 μL water)
and KflA in buffer B (7 μg in 20 μL; 25 mM HCl, 500 mM
NaCl, 250 mM imidazole, pH 8.5) were added to 100 μL
buffer (25 mM Tris–HCl, pH 8.5) and kept at 37°C for 24 h.
For the negative control sample, 20 μL buffer B with no
enzyme was added. The reaction mixture was resolved on
BioGel P-10, and 35S CPM for each fraction was measured
(Packard Tri-Carb 2500 TR) using 100 μL of eluent in 2
mL scintillation fluid (Econo-Safe, Research Products
International, IL). The 6-O-[35S]-sulfo heparosan (3 × 105
CPM, 2.5 μg in 10 μL water) and KflA in buffer B (7 μg in
20 μL; 25 mM HCl, 500 mM NaCl, 250 mM imidazole, pH
8.5) were mixed in 200 μL buffer (25 mM Tris, pH 8.5) at 37°
C for 24 h, followed by P-10 purification and 35S counting as
for the N-[35S]sulfo heparosan sample.
Minimum substrate size requirement of KflA
The dried Hexa-1 and Octa-2 were redissolved in water (see
“Heparosan incubation with KflA”). Each of the two reactions
contained approximately 250 μg of Hexa-1 (in 66 µL H2O) or
Octa-2 (in 40 µL H2O), and KflA (9 μg in 25 µL water)
diluted to a total volume of 525 μL (25 mM Tris–HCl, pH
8.5). After 18 h incubation at 37°C, phenol red (5 μL of
0.5%) was added and the individual mixtures were separated
on a BioGel P-2 column. The fractions were scanned at 232
nm, and fractions corresponding to peaks in the absorbance
vs. fraction plot were analyzed with ESI-MS.
Preparation of heparosan
Both polysaccharides were prepared from heparosan, which is
derived from E. coli K5 and based on a previously reported
method (Vann et al. 1981). E. coli K5 (Bi 8337-41) (50 μL
stock) is added to 100 mL LB media and grown 8 h (37°C).
The culture is expanded with 15 mL of this culture added per
liter of LB media and incubated for 16–18 h (37°C). This
method uses 6 L of culture. The cells are pelleted (4000 × g,
30 min), and the supernatant is filtered and adjusted to pH
5.0. This is diluted 1:1 with buffer A (20 mM sodium acetate,
50 mM NaCl, pH 4.0) and loaded onto a column containing


























100 mL diethylaminoethyl cellulose (DEAE) per 12 L of the
diluted supernatant (flow rate 10 mL/min). After loading, the
column is washed with 1 L buffer A and eluted with 300–
350 mL buffer B (20 mM sodium acetate, 1 M NaCl, pH 4.0).
Ethanol (100%) is added to the eluent and a precipitate is
formed. The eluent is kept overnight at −20°C and centrifuged
(4000 × g, 30 min, 5°C). The pellet is resuspended in 25 mL
H2O. A solution of 4 M ammonium sulfate is added to give a
1:1 mixture. This is cooled on ice for 15 min, then centri-
fuged (3500 × g, 30 min). The gel-like precipitate is saved and
the supernatant is removed and precipitated again with the
addition of ammonium sulfate to 60%. This is centrifuged
(3500 × g, 30 min) and the precipitate is combined with the
previous precipitate and resuspended in 10 mL H2O. This is
dialyzed overnight against H2O with MWCO 12,000–14,000.
The average MW of heparosan isolated from E. coli K5 strain
is about 30 kDa (Vann et al. 1981).
35S labeled N-[35S]-sulfo heparosan and 6-O-[35S]-sulfo
heparosan
The synthesis of 35S-labeled 6-O-[35S]-sulfo heparosan and
N-[35S]-sulfo heparosan has been discussed (Peterson and Liu
2010). To prepare N-[35S]-sulfo heparosan, the heparosan was
first deacetylated under basic conditions and subsequently
dialyzed. The heparosan or chemically deacetylated heparosan
was sulfated with three molar equivalents of [35S] 3′-
phosphoadenosine-5′-phosphosulfate (PAPS) and its respective
sulfotransferase enzyme (6-OST-1 and -3 isoforms, or NST). The
reaction mixtures were purified by a DEAE column. A bed
volume of 0.2 mL DEAE was used for approximately 10 µg of
substrate. The column was washed with 1 mL H2O (2×), 1 mL 1
M NaCl (2×), 1 mL 250 mM NaCl (2×) and equilibrated with 1
mL DEAE buffer (2 × 1 mL) (50 mM sodium acetate, 150 mM
NaCl, 3 M urea, 2 mM ethylenediaminetetraacetic acid, 0.01%
Triton X-100). The reaction mixture is loaded onto the column,
which is then washed with DEAE buffer (4×) and 250 mM NaCl
(4×). The sulfated polysaccharide is eluted with 1 mL of 1 M
NaCl, dialyzed and dried.
Synthesis of Octa-3, Octa-4, Nona-5, Deca-6
A detailed description of the general method for the synthesis
of heparin-like oligosaccharides has been given before (Liu
et al. 2010). The starting compound GlcA-pNP (Sigma, MO)
was mixed with roughly equimolar amounts of UDP-GlcNAc
and 0.1 g/L KfiA and incubated overnight at 37°C. High per-
formance liquid chromatography (HPLC) (YMC polyamine II
column) was used to insure that the reaction had run to ≥95%
completion. After completion, UDP-GlcA (1.1 equimolar)
and pmHS2 (0.1 g/L) were added to the reaction mixture,
incubated (37°C) and again monitored with HPLC. The pro-
ducts of the reaction were purified with a BioGel P-10
column, and the trisaccharide was dialyzed (MWCO 1000),
dried and elongated with two additional cycles. GlcNTFA
residue was incorporated into the chain by substituting
UDP-GlcNAc with UDP-GlcNTFA in the third cycle. A final
addition of GlcNAc followed by P-10 purification and drying
gave Octa-3, which was the basis of the other three synthetic
substrates. The position of the GlcNTFA group was selective-
ly N-sulfated at the position of the GlcNTFA. This was done
by first hydrolyzing the GlcNTFA to the free amine (triethyla-
mine in methanol/water), followed by drying. The resulting
de-N-trifluoroacetylated octasaccharide was sulfated with 3 M
equivalents of PAPS in the presence of NST (overnight, 37°
C), the reaction mixture was purified on a BioGel P-2 column
and the product was dried. To obtain Nona-5, a sample of free
amine octasaccharide was extended once with pmHS2 cata-
lyzed addition of UDP-GlcA, purified on a BioGel P-2
column and dried. The resulting nonasaccharide was sulfated
(PAPS and NST), purified on P-2 and dried. Deca-6 was
obtained from Nona-5 by adding UDP-GlcNAc (KfiA), fol-
lowed by P-2 purification and drying. The identity of each of
the final products was confirmed by ESI-MS.
Synthesis of GlcNTFA and PAPS
A chemoenzymatic method was used to synthesize GlcNTFA
(Liu et al. 2010; Zhou et al. 2011). The starting material
GlcNH2 1-phosphate was reacted with S-ethyl trifluorothioace-
tate to give GlcNTFA 1-phosphate, which was condensed with
uridine diphosphate with glucosamine-1-phosphate acetyl-
transferase/N-acetylglucosamine-1-phosphate uridyltransferase
(GlmU). GlmU is expressed in E. coli and purified with a
nickel sepharose column. The sulfotranferase co-factor PAPS
is also synthesized by a chemoenzymatic method, starting from
adenosine triphosphate (ATP) (Zhou et al. 2011). In a one pot
reaction, ATP is mixed with organic sulfate and is phosphory-
lated at the 3′ position by adenosine 5′-phosphosulfate (APS)
kinase, while ATP sulfurylase hydrolytically cleaves pyrophos-
phate and replaces it with sulfate to give PAPS. The reaction is
carried out in the presence of pyrophosphatase to drive the re-
action toward product. PAPS is purified from the reaction
mixture using a DEAE column. The three enzymes used are
expressed in E. coli as (His)6-tagged fusions and purified with
a nickel column.
Cleavage of synthetic oligosaccharides
All reactions were carried out in 525 μL (Tris–HCl 25 mM,
pH 8.5) total volume containing 9 μg of KflA (in 25 μL
buffer: 25 mM Tris–HCl, 500 mM NaCl, 250 mM imidazole,
pH 8.5) at 37°C for 18 h. Approximately 100–300 μg of sub-
strate was contained in each reaction. For Octa-3 and Octa-4,
100 μg of substrate was added; 300 μg of Nona-5; 200 μg of
Deca-6 was used. The reaction mixture was separated on
BioGel P-2 and fractions were scanned at 232 and 310 nm. A
sample of each fraction was analyzed with ESI-MS.
Electrospray ionization mass spectrometry analysis
All mass spectrometry was done using electrospray negative
ionization on a Thermo LCQ Deca. Eluent from P-2 column
or from dialyzed P-10 fractions (1 μL for heparosan digest,
15 μL for all other oligosaccharides) was added to 200 μL in
8:2 water/methanol. The sample was injected by a syringe
pump (Hamilton, NV) at 35 μL/min. Nonsulfated oligosac-
charides were ionized at 5 kV potential and 275°C, with sul-
fated oligosaccharides at 3 kV and 175°C. Scans were
averaged over 1 min and data were analyzed with Xcalibur
software.



























Supplementary data for this article is available online at http://
glycob.oxfordjournals.org/.
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N-trifluoroacetyl glucosamine; GlmU, glucosamine-1-phosphate
acetyl-transferase/N-acetylglucosamine-1-phosphate uridyltrans-
ferase; HPLC, high performance liquid chromatography; HS,
heparan sulfate; Hexa-1, Δ4,5 hexasaccharide; IdoA, iduronic acid;
KflA, K5 lyase A; LB, Luria-Bertani; MS, mass spectrometry;
MWCO, molecular weight cutoff; NST, N-sulfotransferase;
Octa-2, Δ4,5 octasaccharide; 6-OST-1 and -3, 6-O-sulfotransferase
1 and 3; PAPS, [35S] 3′-phosphoadenosine-5′-phosphosulfate;
PCR, polymerase chain reaction; pmHS2, Pasteurella multocida
heparosan synthase; pNP, para-nitrophenol; SDS–PAGE, sodium
dodecylsulfate polyacrylamide gel electrophoresis; UDP, uridine
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